Life Sciences

  • May 05, 2026

    Sandoz, Novartis Must Face Generics Claims From GM, Others

    A Pennsylvania federal judge largely refused to let dozens of generic-drug makers duck stand-alone price-fixing and market allocation antitrust claims from major employers like General Motors, American Airlines and Lowe's, nixing allegations against a small handful while importantly preserving them against Novartis and its former Sandoz subsidiary.

  • May 05, 2026

    Deutsche, Pathward Want Fintech Blacklist Suit Tossed

    Deutsche Bank AG and Pathward NA urged a New York federal court to dismiss a suit accusing them of improperly blacklisting a barter-based payment platform that the banks found was "transaction laundering" for companies selling gray-market pharmaceuticals, arguing that the suit's jurisdiction assertions are fatal to the claims.

  • May 05, 2026

    Travelers Unit Says No Coverage In Cannabis Explosion Suits

    A Travelers Property Casualty Corp. unit is suing two of its insureds in California federal court, seeking a declaration that its insurance policies don't cover defense and indemnity of suits over a deadly explosion allegedly caused by an illegal cannabis operation.

  • May 04, 2026

    'They Knew It': J&J Accused Of Hiding Talc Risk At LA Trial

    Johnson & Johnson knew for decades that its baby powder contained asbestos, even as it advertised the product as safe and "pure," attorneys for the families of three women who died of ovarian cancer told a California jury Monday during opening statements in a bellwether trial.

  • May 04, 2026

    Biotech Overhyping Obesity Drug Hurt Investors, Suit Says

    Current and former executives of drugmaker Skye Bioscience Inc. breached their fiduciary duties by overstating an obesity drug's clinical prospects and precipitating a trading price decline when the company revealed disappointing study results, an investor has alleged.

  • May 04, 2026

    Judge Shuts Down Invalidity Theory In Abiomed IP Case

    A Massachusetts federal judge has foreclosed one of Abiomed's invalidity defenses in a case brought by rival medical technology firm Maquet over alleged infringement of a patent covering blood pump technology.

  • May 04, 2026

    Supplement Co. Says False Labeling Plaintiff Never Saw Ads

    The maker of Thesis Nootropics supplements is asking a New York federal court to throw out claims that it falsely advertises its products as ADHD medications, saying the plaintiff hasn't sufficiently alleged she ever saw the advertisements or even used the products.

  • May 04, 2026

    Supreme Court Halts Abortion Drug Telehealth Ruling

    The U.S. Supreme Court on Monday temporarily reinstated telehealth access for the abortion medication mifepristone, pausing a lower-court order that had blocked by-mail and remote prescriptions.

  • May 04, 2026

    Justices Won't Hear Anti-Vaxxer Medical Board Suit

    The U.S. Supreme Court on Monday said it will not review a petition brought by Health and Human Services Secretary Robert F. Kennedy Jr. on behalf of doctors who challenged a Washington state medical board's investigation into an alleged COVID-19 misinformation campaign.

  • May 01, 2026

    Pharma Aims Torpedo At FCA After Bombshell 9th Circ. Ruling

    A burgeoning campaign against the False Claims Act's whistleblower mechanism is suddenly center stage at the Ninth Circuit, where pharmaceutical companies say a momentous new ruling "illustrates perfectly" the constitutional concerns of U.S. Supreme Court justices regarding FCA enforcement.

  • May 01, 2026

    Judge, Atty Get In Shouting Match At Fatal Overdose Trial

    Tensions boiled over in a Philadelphia courtroom Friday at the end of an emotionally fraught trial over a man's fatal opioid overdose, with a judge and lawyer shouting at each other about how to figure out an inconclusive verdict spurred by a seemingly confused juror.

  • May 01, 2026

    Twist Bioscience Investors Seek $17M Stock Fraud Deal OK

    Twist Bioscience Corp. and two executives asked a California federal court to give preliminary approval to a $17 million deal they inked with investors to resolve class allegations the company misrepresented that its technology could produce synthetic DNA at higher quality and lower cost than competitors.

  • May 01, 2026

    Amazon Accused Of Selling Kids Sunscreen With Lead

    Consumers on Thursday hit Amazon with a proposed class action in Washington federal court alleging that children's sunscreens it sells are contaminated with heavy metals such as lead and that its artificial intelligence shopping assistant Rufus doesn't disclose details about the product ingredients.

  • May 01, 2026

    Fla. Jury Hears Menthol Smoker Succumbed To Addiction

    A Florida jury heard in opening arguments Friday that a woman who died of lung cancer after smoking R.J. Reynolds cigarettes was a victim of the severely addictive nature of nicotine, something her lawyers said even the U.S. surgeon general didn't acknowledge until 1988.

  • May 01, 2026

    Texas High Court Revives Delta-8 THC Restrictions

    The Lone Star State's health commissioner has the power to ban manufactured delta-8 THC goods, the Texas Supreme Court ruled Friday, lifting a lower court's order that had allowed hemp companies to keep selling these products while they sued the state.

  • May 01, 2026

    Biotech IPOs Surge Ahead As 2 Listings Raise $557M

    A pair of biotechnology firms began trading on Friday after raising a combined $557 million through upsized initial public offerings that both priced at the top of their proposed $16 to $18 ranges, marking the latest drug developers to join the IPO market in recent weeks.

  • May 01, 2026

    5th Circ. Pauses Mail-Order Access To Abortion Pills

    The Fifth Circuit on Friday reinstated an in-person dispensing requirement for the abortion medication mifepristone, blocking mail-order access while a challenge to a Biden administration regulation brought by Louisiana officials moves forward.

  • May 01, 2026

    Pharma Co. Investor Sues Over Misleading Aurinia Deal

    A Kezar Life Sciences investor has filed suit asking an Illinois federal judge to halt the company's planned acquisition by a Canadian biopharmaceutical company's U.S. unit unless Kezar fixes the "incomplete and misleading" regulatory filings it submitted regarding the transaction.

  • May 01, 2026

    Biotech Firm Wants Do-Over After Consultant's $58M Verdict

    A Georgia-based medical technology firm that was hit with a $58 million verdict last month over claims that it conspired to have a former consultant arrested has asked a Fulton County judge for a new trial, arguing the court allowed a jury charge that was "erroneous, irrelevant, [and] not tailored to the evidence."

  • May 01, 2026

    Vietnam Tops USTR Priority IP Watch List In Latest Report

    Vietnam hasn't dealt with "long-standing" issues to protect and enforce intellectual property rights, and its actions have had the biggest negative impact on U.S. products, according to the Office of the U.S. Trade Representative's latest annual global IP report.

  • May 01, 2026

    How Paul Clement Does It All

    For most lawyers, getting to argue before the U.S. Supreme Court is a once-in-a-lifetime event, but for a select few, it's a common occurrence. Clement & Murphy PLLC name partner Paul Clement is one of those lawyers. 

  • May 01, 2026

    Sidley, Goodwin Lead $1.1B Take-Private Deal For Esperion

    Biopharmaceutical company Esperion Therapeutics, advised by Goodwin Procter LLP, on Friday announced plans to go private after being bought by Sidley Austin LLP-led healthcare-focused investment firm Archimed in a $1.1 billion deal.

  • May 01, 2026

    Mylan Inks $11M Deal With NC Over EpiPen Pricing

    North Carolina Attorney General Jeff Jackson announced Thursday that the state has inked an $11 million settlement with EpiPen distributor Mylan Pharmaceuticals, resolving claims of anticompetitive conduct and funneling millions back into public healthcare programs.

  • April 30, 2026

    Medtronic User Says Data Hack Exposed 9M Client Records

    A Medtronic customer filed a proposed class action Thursday accusing the medical device company of failing to safeguard more than 9 million records containing personally identifiable information — including health information — exposed in a data breach earlier this month.

  • April 30, 2026

    Acadia Investors Get Final OK For $179M Deal, Atty Fees

    A Tennessee federal judge has given final approval to a $179 million settlement between investors and Acadia Healthcare Co. Inc., ending a class action that alleged the company misled investors about the strength of its U.K. operations.

Expert Analysis

  • Series

    Watching Hallmark Movies Makes Me A Better Lawyer

    Author Photo

    I realize you may be judging me for watching, and actually enjoying, Hallmark Channel movies, but the escapism and storylines actually demonstrate qualities and actions that lead to an efficient, productive and positive legal practice, says Karen Ross at Tucker Ellis.

  • New Orphan Drug Law Provides A Key Fix For Pharma Cos.

    Author Photo

    The Consolidated Appropriations Act enacted last month restores the U.S. Food and Drug Administration's long-standing interpretation of "same disease or condition," related to orphan drug exclusivity, resolving years of regulatory uncertainty and litigation that have discouraged rare disease research, say attorneys at Spencer Fane.

  • When Trade Secret Litigation And Criminal Law Collide

    Author Photo

    An increasing convergence of trade secret litigation and white collar defense, especially with several recent criminal prosecutions from the Justice Department, should prompt businesses and counsel to adapt within the overlapping landscapes, says Kenneth Notter at MoloLamken.

  • Opinion

    PTAB Needs Reform To Protect Inventors From Larger Cos.

    Author Photo

    The Promoting and Respecting Economically Vital American Innovation Leadership Act is necessary because it will impose additional requirements on patent validity challenges and prevent large corporations from taking advantage of the Patent Trial and Appeal Board to overwhelm small inventors with repeated litigation, says Eb Bright at ExploraMed Development.

  • FDA User Fee Talks Offer Clues On Upcoming Reforms

    Author Photo

    As the U.S. Food and Drug Administration undergoes the User Fee Act reauthorization process and renegotiates its user fee agreements over the next several months, the agency's consultation meetings with relevant industries can shed light on the FDA's priorities, and provides stakeholders an opportunity to participate in the reform process, say attorneys at Holland & Knight.

  • Moderna Case Highlights Overlooked Hurdle In Biopharma IP

    Author Photo

    The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.

  • FDA Framework For Personalized Therapies Raises Questions

    Author Photo

    The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.

  • Emissions Permits May Not Override Pollution Exclusions

    Author Photo

    Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.

  • 5 Tips For Navigating Your Firm's All-Attorney Summit

    Excerpt from Practical Guidance
    Author Photo

    Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.

  • Series

    Coaching Soccer Makes Me A Better Lawyer

    Author Photo

    Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

  • Avoid The Unexpected When Drafting License Agreements

    Author Photo

    The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.

  • CMS Healthcare Enforcement Initiatives May Cause Disruption

    Author Photo

    The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.

  • The Benefits Of Choosing A Niche Practice In The AI Age

    Author Photo

    As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.

  • How PBMs Can Adapt To Plan Sponsors' Disclosure Demands

    Author Photo

    As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.